Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma

Cancer Science

Volumn 103, Issue 5, 2012, Pages 868-874

  Yoshikawa, Yoshie ^a,c   Sato, Ayuko ^a   Tsujimura, Tohru ^a   Emi, Mitsuru ^a,b   Morinaga, Tomonori ^a   Fukuoka, Kazuya ^a   Yamada, Shusai ^a   Murakami, Aki ^a   Kondo, Nobuyuki ^a   Matsumoto, Seiji ^a   Okumura, Yoshitomo ^a   Tanaka, Fumihiro ^a   Hasegawa, Seiki ^a   Nakano, Takashi ^a   Hashimoto Tamaoki, Tomoko ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c Itami City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN;

ARTICLE; CLINICAL ARTICLE; EXON; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE INACTIVATION; GENETIC ASSOCIATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MISSENSE MUTATION; NONSENSE MUTATION; PATHOGENESIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

CELL LINE, TUMOR; GENE DELETION; HUMANS; MESOTHELIOMA; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84860248968     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02223.x     Document Type: Article

References (20)

1. Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980; 46: 2736-40.
2. Nojiri S, Gemba K, Aoe K et al. Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan. Jpn J Clin Oncol 2011; 41: 32-9.
3. Neragi-Miandoab S. Multimodality approach in management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006; 29: 14-9.
4. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995; 11: 511-55.
5. Prins JB, Williamson KA, Kamp MM et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998; 75: 649-53.
6. Sekido Y, Pass HI, Bader S et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55: 1227-31.
7. Bianchi AB, Mitsunaga SI, Cheng JQ et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995; 92: 10854-8.
8. Kratzke RA, Otterson GA, Lincoln CE et al. Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma. J Natl Cancer Inst 1995; 87: 1870-5.
9. Papp T, Schipper H, Pemsel H et al. Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 2001; 18: 425-33.
10. Yoshikawa Y, Sato A, Tsujimura T et al. Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells. Int J Oncol 2011; 39: 1365-74.
11. Jensen DE, Proctor M, Marquis ST et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998; 16: 1097-112.
12. Nishikawa H, Wu W, Koike A et al. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer Res 2009; 69: 111-9.
13. Harbour JW, Onken MD, Roberson ED et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410-3.
14. Ventii KH, Devi NS, Friedrich KL et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008; 68: 6953-62.
15. Bott M, Brevet M, Taylor BS et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43: 668-72.
16. Wiesner T, Obenauf AC, Murali R et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43: 1018-21.
17. Testa JR, Cheung M, Pei J et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43: 1022-5.
18. Abdel-Rahman MH, Pilarski R, Cebulla CM et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011; 48: 856-9.
19. Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1. J Biol Chem 2009; 284: 34179-88.
20. Misaghi S, Ottosen S, Izrael-Tomasevic A et al. Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol 2009; 29: 2181-92.